Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning.
Author | |
---|---|
Abstract |
:
Boron neutron capture therapy (BNCT) using 4-[10B]boronophenylalanine-fructose (BPA-Fr) is in Phase II clinical trials to validate BNCT as a treatment for glioblastoma multiforme and melanoma. Successful BNCT depends on knowledge of the distribution of boron-containing agents in both tumor and normal tissue as currently determined by chemical confirmation of boron deposition in surgically removed malignant tissue before BNCT. |
Year of Publication |
:
1997
|
Journal |
:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
|
Volume |
:
38
|
Issue |
:
11
|
Number of Pages |
:
1762-7
|
ISSN Number |
:
0161-5505
|
URL |
:
http://jnm.snmjournals.org/cgi/pmidlookup?view=long&pmid=9374349
|
Short Title |
:
J Nucl Med
|
Download citation |